Literature DB >> 29223737

Synthesis and characterization of small-sized gold nanoparticles coated by bovine serum albumin (BSA) for cancer photothermal therapy.

Selma M H Al-Jawad1, Ali A Taha2, Mohammad M F Al-Halbosiy3, Lamyaa F A Al-Barram4.   

Abstract

In the present study, small gold nanoparticles <5 nm coated with natural protein Bovine Serum Albumin (BSA) was synthesized and characterized using UV-vis spectrophotometer, Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM), zeta potential and scanning electron microscopy (SEM). Three types of cancer cell lines; Rhabdomyosarcoma (RD), Murine fibroblast (L20B) and RAW 264.7 monocyte-macrophage (MQ) were tested and treated by photothermal strategy, in vitro, by conjugating BSA-AuNPs complex of (0.125, 0.25, 0.5 and 1 mg/ml) concentrations with continuous low power laser irradiation, green (532 nm) and near-infrared (NIR) (800 nm) at 0.5, 1, 2 and 3 min, separately. Cytotoxicity effect was determined by MTT assay. The vital impact of photothermal technique has investigated at 1 mg/ml and 3 min irradiation period as identified in RD cell line in comparison with other types; where cytotoxicity more than 74% was reached. Prominent results were demonstrated in the green and NIR region by pH -induced aggregation effect of small nanoparticles inside the cancer cells, which make the small-sized BSA-AuNPs are promising agents for cancer photothermal therapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BSA; Cytotoxicity; Photothermal therapy (PPT); Renal clearance; Small-sized gold nanoparticles

Mesh:

Substances:

Year:  2017        PMID: 29223737     DOI: 10.1016/j.pdpdt.2017.12.004

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  8 in total

1.  Biocompatible quantum dot-antibody conjugate for cell imaging, targeting and fluorometric immunoassay: crosslinking, characterization and applications.

Authors:  Soubhagya Laxmi Sahoo; Chi-Hsien Liu; Monika Kumari; Wei-Chi Wu; Chun-Chao Wang
Journal:  RSC Adv       Date:  2019-10-15       Impact factor: 4.036

Review 2.  A health concern regarding the protein corona, aggregation and disaggregation.

Authors:  Mojtaba Falahati; Farnoosh Attar; Majid Sharifi; Thomas Haertlé; Jean-François Berret; Rizwan Hasan Khan; Ali Akbar Saboury
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-02-22       Impact factor: 3.770

Review 3.  Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.

Authors:  Yao Chen; Juan Yang; Shaozhi Fu; Jingbo Wu
Journal:  Int J Nanomedicine       Date:  2020-11-24

4.  Exploring the Conformation and Thermal Stability of Human Serum Albumin Corona of Ferrihydrite Nanoparticles.

Authors:  Claudia G Chilom; Adriana Bălan; Nicoleta Sandu; Maria Bălăşoiu; Sergey Stolyar; Oleg Orelovich
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

5.  Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer.

Authors:  Susu Xiao; Huan Shi; Yan Zhang; Yu Fan; Li Wang; Li Xiang; Yanlin Liu; Ling Zhao; Shaozhi Fu
Journal:  J Nanobiotechnology       Date:  2022-04-02       Impact factor: 10.435

6.  Biomimetic Keratin-Coated Gold Nanoparticles for Photo-Thermal Therapy in a 3D Bioprinted Glioblastoma Tumor Model.

Authors:  Maila Chirivì; Claudia Bearzi; Paolo Rosa; Selenia Miglietta; Francesca Petronella; Elena De Falco; Antonella Calogero; Roberto Pani; Vincenzo Petrozza; Giovanni Perotto; Roberto Rizzi; Luciano De Sio
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

Review 7.  Capping gold nanoparticles with albumin to improve their biomedical properties.

Authors:  Karen Bolaños; Marcelo J Kogan; Eyleen Araya
Journal:  Int J Nanomedicine       Date:  2019-08-09

8.  Multi-Lens Arrays (MLA)-Assisted Photothermal Effects for Enhanced Fractional Cancer Treatment: Computational and Experimental Validations.

Authors:  Hyejin Kim; Hanjae Pyo; Hyeonsoo Kim; Hyun Wook Kang
Journal:  Cancers (Basel)       Date:  2021-03-08       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.